Aratana Therapeutics, Inc. (PETX): Craig A Tooman , CHIEF FINANCIAL OFFICER of Aratana Therapeutics, Inc. sold 30,000 shares on Sep 9, 2016. The Insider selling transaction was reported by the company on Sep 12, 2016 to the Securities and Exchange Commission. The shares were sold at $9.25 per share for a total value of $277,599.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Aug 10, 2016, Peter Steven St (PRESIDENT AND CEO) sold 50,000 shares at $9.25 per share price.On Jun 28, 2016, Julia A Stephanus (CHIEF COMMERCIAL OFFICER) sold 30,000 shares at $6.25 per share price.Also, On Jun 13, 2016, Ernst Heinen (Chief Development Officer) sold 15,000 shares at $6.72 per share price.On Feb 2, 2016, Craig A Tooman (CHIEF FINANCIAL OFFICER) sold 2,806 shares at $3.36 per share price.
Aratana Therapeutics Inc: On Monday, Sep 12, 2016 heightened volatility was witnessed in Aratana Therapeutics Inc which led to swings in the share price. The shares opened for trading at $8.91 and hit $9.22 on the upside , eventually ending the session at $9.21, with a gain of 0.88% or 0.08 points. The heightened volatility saw the trading volume jump to 702,692 shares. The 52-week high of the share price is $19.9896 and the company has a market cap of $326 M . The 52-week low of the share price is at $2.56.
Company has been under the radar of several Street Analysts.Aratana Therapeutics Inc is Resumed by Lake Street to Buy and the brokerage firm has set the Price Target at $15. The Rating was issued on Sep 6, 2016.Aratana Therapeutics Inc is Resumed by Jefferies to Buy. The Rating was issued on Aug 19, 2016.
Aratana Therapeutics Inc. is a pet therapeutics company focused on licensing developing and commercializing of biopharmaceutical products for companion animals. The Company has licensed and is developing more than 18 therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target serious medical conditions such as pain and inflammation stimulation of appetite cancer and other serious diseases for dogs and cats. These product candidates are in various stages of development for the treatment of cats or dogs or both. The Company’s target indications include pain and inflammation associated with osteoarthritis inappetence post-operative pain lymphoma osteosarcoma atopic dermatitis ocular herpes and feline immunodeficiency virus. The Company’s most advanced products from a development and commercialization perspective AT-004 and AT-005 are monoclonal antibodies (MAbs) for treating lymphoma in dogs.